This article from Satya amid the fallout from everyone getting rugpulled from Anthropic makes an extremely compelling case for both Sovereign AI (basically @cohere) and now Sovereign Knowledge Infrastructure.

Long non-coding RNAs will be the next gold mine for novel drug targets. In the past two weeks, we saw two major partnerships announced, specifically hunting for lncRNA targets: @HAYA_lncRNA and @EliLillyandCo - $1B+ NextRNA and @Bayer - $550M+ The hardest part is deciding which lncRNA to target. LncRNAs have cell-type, tissue-type, and disease specific expression patterns. They're involved in complex and often pleiotropic biological processes. Epigenetics is notoriously hard. You have to integrate bioinformatic data from all kinds of experiments (ChIP, ChIRP, RIP, eCLIP, ATAC, etc...) to understand the epigenetic landscape and test your hypotheses. "What does my lncRNA bind with?" and "Where does the lncRNA-protein complex bind to on the genome?" and "Are they promoters? Enhancers? Is the region even accessible in my cell type? Tissue? Disease?" and "Do those genes show expression changes when I knock down my lncRNA?" These types of multi-hop questions are where knowledge graphs shine. Traversing these paths and finding patterns become trivial once you've modeled and loaded the data into a knowledge graph on the @BioBoxAnalytics platform. Interested in learning more? DM me and let's chat. #ncRNA #epigenetics #KnowledgeGraph

Platform therapeutic companies that can zero-in on high quality causal drug targets will win in the next decade. Lauren Phillips(@LaurenP23_) discusses the impact in our latest blog post 👇 Bottom line is that drug discovery is a business activity, which disincentivizes therapeutic development in rare diseases with smaller market sizes. New FDA guidelines look to shake things up, providing a path for platform companies to massively fast track therapeutic development. blog.biobox.io/p/from-techno…

🚀Excited to share our latest update to the @BioBoxAnalytics platform. Introducing the Graph Explorer - a seamless way to build a GPS for disease biology in drug discovery. Interactively explore a canvas of highly connected multi-modal biological data, all in one place. To learn more, you can read about it here: blog.biobox.io/p/building-a-…

Thrilled to collaborate with leading AI researchers at @VectorInst through this partnership! linkedin.com/posts/toronto-i…

Having data is not the same as having knowledge. Big pharma teams are using Knowledge Graphs to accelerate drug discovery and get assets to market faster. Here's how they do it: blog.biobox.io/p/beyond-data…